Abstract
Background: Elevated levels of serum LDL and total cholesterol are considered important risk factors for the development of atherosclerosis. Cholesteryl ester transfer protein inhibition raises HDL levels and reduces atherosclerotic lesions.
Objective: Consequently, there is a great interest in developing new CETP inhibitors.
Methods: Herein, synthesis of four chlorobenzyl benzamides 8a-d that aim at CETP inhibition was performed.
Results: Benzamide 8a showed the best CETP inhibitory activity with an IC50 of 1.6 µM. In vitro biological data shows that the presence of p-trifluoromethoxy group enhances CETP inhibitory activity more than m-trifluoromethyl groups. QPLD docking shows that the verified compounds accommodate the binding cleft of CETP and are enclosed by hydrophobic lining. The scaffold of 8a-d matches the pharmacophoric points of CETP inhibitors; particularly hydrophobic and aromatic functionalities.
Conclusion: Future structural modification is needed to improve CETP inhibitory activity and to enhance understanding of the structure-activity relationship.
Keywords: Atherosclerosis, CETP inhibitors, chlorobenzyl benzamides, docking, QPLD, pharmacophore mapping.
Letters in Drug Design & Discovery
Title:CETP Inhibitory Activity of Chlorobenzyl Benzamides: QPLD Docking, Pharmacophore Mapping and Synthesis
Volume: 14 Issue: 12
Author(s): Reema Abu Khalaf*, Hamada Abd El-Aziz, Dima Sabbah, Ghadeer Albadawi and Ghassan Abu Sheikha
Affiliation:
- Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman,Jordan
Keywords: Atherosclerosis, CETP inhibitors, chlorobenzyl benzamides, docking, QPLD, pharmacophore mapping.
Abstract: Background: Elevated levels of serum LDL and total cholesterol are considered important risk factors for the development of atherosclerosis. Cholesteryl ester transfer protein inhibition raises HDL levels and reduces atherosclerotic lesions.
Objective: Consequently, there is a great interest in developing new CETP inhibitors.
Methods: Herein, synthesis of four chlorobenzyl benzamides 8a-d that aim at CETP inhibition was performed.
Results: Benzamide 8a showed the best CETP inhibitory activity with an IC50 of 1.6 µM. In vitro biological data shows that the presence of p-trifluoromethoxy group enhances CETP inhibitory activity more than m-trifluoromethyl groups. QPLD docking shows that the verified compounds accommodate the binding cleft of CETP and are enclosed by hydrophobic lining. The scaffold of 8a-d matches the pharmacophoric points of CETP inhibitors; particularly hydrophobic and aromatic functionalities.
Conclusion: Future structural modification is needed to improve CETP inhibitory activity and to enhance understanding of the structure-activity relationship.
Export Options
About this article
Cite this article as:
Abu Khalaf Reema *, Abd El-Aziz Hamada, Sabbah Dima, Albadawi Ghadeer and Abu Sheikha Ghassan, CETP Inhibitory Activity of Chlorobenzyl Benzamides: QPLD Docking, Pharmacophore Mapping and Synthesis, Letters in Drug Design & Discovery 2017; 14 (12) . https://dx.doi.org/10.2174/1570180814666170412122304
DOI https://dx.doi.org/10.2174/1570180814666170412122304 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in Experimental Myocarditis
Current Pharmaceutical Design Selective Removal of Macrophages in Atherosclerotic Plaques as a Pharmacological Approach for Plaque Stabilization: Benefits Vs. Potential Complications
Current Vascular Pharmacology Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science Lipid-lowering Therapy in the Diabetic Foot: Seeing the Whole Iceberg and not Just the Tip
Current Vascular Pharmacology Obesity, Metabolic Syndrome, Diabetes and Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs Effect of Chronic Melatonin Administration on Several Physiological Parameters from Old Wistar Rats and Samp8 Mice
Current Aging Science Outcome of Heart Failure with Preserved Ejection Fraction: A Multicentre Spanish Registry
Current Cardiology Reviews Efficacy and Safety Evaluation of Fixed Dose Combination of Cefepime and Amikacin in Comparison with Cefepime Alone in Treatment of Nosocomial Pneumonia Patients
Current Clinical Pharmacology Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design Melatonin and Renal Protection: Novel Perspectives from Animal Experiments and Human Studies (Review)
Current Pharmaceutical Design High-density Lipoprotein, Vascular Risk, Cancer and Infection: A Case of Quantity and Quality?
Current Medicinal Chemistry Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs as Cyclooxygenase Inhibitors: State of the Art, Barriers and Perspectives
Current Computer-Aided Drug Design Living Heart Valve and Small-Diameter Artery Substitutes - An Emerging Field for Intellectual Property Development
Recent Patents on Biotechnology Are Topological Properties of Drug Targets Based on Protein-Protein Interaction Network Ready to Predict Potential Drug Targets?
Combinatorial Chemistry & High Throughput Screening Nutrition and Physical Activity on Hypertension: Implication of Current Evidence and Guidelines
Current Hypertension Reviews Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?
Cardiovascular & Hematological Disorders-Drug Targets Genetic Polymorphism of LDLR (rs688) is Associated with Primary Intracerebral Hemorrhage
Current Neurovascular Research Organoselenium Compounds as Potential Therapeutic and Chemopreventive Agents: A Review
Current Medicinal Chemistry